Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avanir Pharmaceuticals has introduced that Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) as a treatment for pseudobulbar affect (PBA).
Subscribe to our email newsletter
Nuedexta is a combination of two components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations.
Avanir Pharma said that to support the availability of Nuedexta for all patients with PBA, it has started several patient support services such as a reimbursement counseling hotline and a co-pay assistance program.
Avanir Pharma president and CEO Keith Katkin said after years of hard work and perseverance, the availability of Nuedexta is an important milestone for the many patients in the US suffering from PBA who now have access to a safe, effective treatment.